About: Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Sector: Healthcare
Industry: Biotechnology
Latest price: $29.32 (-0.64%)
LKFT NASDAQ Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV share price
LKFT price activity
Último preço
$ 29,320
Variação (24h)
-0,19 USD (-0,64%)
Volume
452.12K
Volume (média 4 sem.)
-
Abertura
$ 29,75
Variação do dia
$ 29,09 - $ 29,90
Fechamento anterior
$ 29,51
Último negócio
06 Oct, 8:00 pm GMT+0
Atrasado
06 Oct, 8:00 pm GMT+0
LKFT price performance
Atrasado
06 Oct, 8:00 pm GMT+0
quote.marketSignals